Kuros Biosciences AG (SWX:KURN)
Switzerland · Delayed Price · Currency is CHF 27.46
+0.88 (3.31%)
Aug 14, 2025, 5:31 PM CET
Kuros Biosciences AG Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 103.35 | 75.56 | 33.56 | 17.99 | 13.82 | 4.04 | Upgrade | |
Revenue Growth (YoY) | 140.06% | 125.11% | 86.61% | 30.19% | 242.04% | 57.71% | Upgrade |
Cost of Revenue | 11.67 | 8.42 | 5.09 | 3.62 | 3.75 | 2.37 | Upgrade |
Gross Profit | 91.68 | 67.13 | 28.47 | 14.37 | 10.07 | 1.67 | Upgrade |
Selling, General & Admin | 80.14 | 60.16 | 31.78 | 19.38 | 14.05 | 9.66 | Upgrade |
Research & Development | 7.68 | 6.98 | 2.03 | 5.19 | 4.99 | 4.01 | Upgrade |
Other Operating Expenses | 0 | -0.12 | -0.25 | -0.36 | -0.21 | -0.2 | Upgrade |
Operating Expenses | 87.82 | 67.03 | 33.56 | 24.22 | 18.83 | 13.46 | Upgrade |
Operating Income | 3.86 | 0.11 | -5.09 | -9.85 | -8.77 | -11.79 | Upgrade |
Interest Expense | -5.23 | -0.15 | -0.19 | - | -1.38 | -0.85 | Upgrade |
Interest & Investment Income | - | - | - | - | 0.6 | 0.43 | Upgrade |
Currency Exchange Gain (Loss) | 1.18 | 1.18 | -2.3 | -0.79 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 0.48 | 0.62 | 2.33 | -1.75 | - | - | Upgrade |
EBT Excluding Unusual Items | 0.28 | 1.76 | -5.24 | -12.39 | -9.55 | -12.2 | Upgrade |
Impairment of Goodwill | -5.1 | -5.1 | -4.37 | -3.6 | - | - | Upgrade |
Asset Writedown | - | - | -0.17 | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | - | 0.11 | Upgrade |
Pretax Income | -4.82 | -3.35 | -9.78 | -15.99 | -9.55 | -12.09 | Upgrade |
Income Tax Expense | 1.08 | 0.37 | 0.38 | -1.4 | -2.01 | -0.57 | Upgrade |
Earnings From Continuing Operations | -5.9 | -3.72 | -10.16 | -14.6 | -7.54 | -11.52 | Upgrade |
Earnings From Discontinued Operations | -0.17 | -0.57 | -3.57 | - | - | - | Upgrade |
Net Income | -6.07 | -4.29 | -13.73 | -14.6 | -7.54 | -11.52 | Upgrade |
Net Income to Common | -6.07 | -4.29 | -13.73 | -14.6 | -7.54 | -11.52 | Upgrade |
Shares Outstanding (Basic) | 46 | 37 | 37 | 34 | 33 | 24 | Upgrade |
Shares Outstanding (Diluted) | 46 | 37 | 37 | 34 | 33 | 24 | Upgrade |
Shares Change (YoY) | 38.66% | 1.69% | 7.91% | 3.37% | 34.86% | 53.69% | Upgrade |
EPS (Basic) | -0.13 | -0.12 | -0.38 | -0.43 | -0.23 | -0.47 | Upgrade |
EPS (Diluted) | -0.13 | -0.12 | -0.38 | -0.43 | -0.23 | -0.47 | Upgrade |
Free Cash Flow | -0.67 | 2.05 | -9.16 | -7.74 | -5.76 | -9.3 | Upgrade |
Free Cash Flow Per Share | -0.01 | 0.06 | -0.25 | -0.23 | -0.18 | -0.38 | Upgrade |
Gross Margin | 88.70% | 88.85% | 84.83% | 79.89% | 72.86% | 41.37% | Upgrade |
Operating Margin | 3.73% | 0.14% | -15.15% | -54.74% | -63.46% | -291.83% | Upgrade |
Profit Margin | -5.87% | -5.68% | -40.90% | -81.15% | -54.59% | -285.22% | Upgrade |
Free Cash Flow Margin | -0.65% | 2.71% | -27.29% | -43.05% | -41.72% | -230.25% | Upgrade |
EBITDA | 5.82 | 2.06 | -2.99 | -7.5 | -6.34 | -9.48 | Upgrade |
EBITDA Margin | 5.64% | 2.72% | -8.91% | -41.70% | -45.90% | -234.81% | Upgrade |
D&A For EBITDA | 1.97 | 1.95 | 2.1 | 2.35 | 2.43 | 2.3 | Upgrade |
EBIT | 3.86 | 0.11 | -5.09 | -9.85 | -8.77 | -11.79 | Upgrade |
EBIT Margin | 3.73% | 0.14% | -15.15% | -54.74% | -63.46% | -291.83% | Upgrade |
Revenue as Reported | 103.35 | 75.56 | 33.56 | 17.99 | 13.82 | 4.04 | Upgrade |
Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.